IXICO plc Result of AGM (4748M)
21 Enero 2021 - 5:05AM
UK Regulatory
TIDMIXI
RNS Number : 4748M
IXICO plc
21 January 2021
IXICO plc
("IXICO" or the "Company")
Results of AGM
IXICO plc (AIM: IXI), the AI digital technologies company
serving neuroscience, announces that all resolutions put forward to
its Annual General Meeting held earlier today were duly passed and
the votes cast were as follows:
Resolution Description Total % Votes Total Votes Withheld
Votes Against
For
1 Reports and Accounts 30,185,052 99.95% 15,600 400
--------------------- ----------- -------- ------------ ---------
2 Re-election of
Directors
Re-election of
Mark Warne 30,185,152 99.95% 15,900 0
Re-election of
John Bradshaw 30,185,452 99.95% 15,600 0
--------------------- ----------- -------- ------------ ---------
Re-appointment
3 of Auditors 30,065,960 99.57% 128,100 6,992
--------------------- ----------- -------- ------------ ---------
Allotment of
4 Securities 30,180,960 99.94% 17,100 2,992
--------------------- ----------- -------- ------------ ---------
Disapply Pre-Emption
5 Provisions 30,180,010 99.94% 18,050 2,992
--------------------- ----------- -------- ------------ ---------
Amendment of
rule 3.6.1 of
the Company's
2014 EMI Share
6 Option Plan 30,165,610 99.89% 33,350 1,992
--------------------- ----------- -------- ------------ ---------
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales)
Walbrook PR Ltd +44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne IXICO@walbrookpr.com
/
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGDKDBPKBKDFDB
(END) Dow Jones Newswires
January 21, 2021 06:05 ET (11:05 GMT)
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024